Halozyme Therapeutics (NASDAQ:HALO) will receive a $10M milestone payment from Johnson & Johnson (NYSE:JNJ)
unit Janssen Biotech triggered by the first commercial sale of
subcutaneous formulation of DARZALEX (daratumumab) in the European
Union.
The product utilizes the company’s Enhanze drug delivery technology that Janssen in-licensed in 2014.
https://seekingalpha.com/news/3584890-halozyme-earns-10m-milestone-from-j-and-j-under-enhanze-license
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.